Cargando…

Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial

OBJECTIVE: SLE is a chronic inflammatory autoimmune disease characterised by the excessive production of autoantibodies, immune complexes and proinflammatory cytokines. Repository corticotropin injection (RCI) is a naturally sourced complex mixture of adrenocorticotropic hormone analogues and other...

Descripción completa

Detalles Bibliográficos
Autores principales:	Askanase, Anca D, Zhao, Enxu, Zhu, Julie, Connolly-Strong, Erin, Furie, Richard A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204552/ https://www.ncbi.nlm.nih.gov/pubmed/32399253 http://dx.doi.org/10.1136/lupus-2020-000383

Ejemplares similares

Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2021)

Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar(®) Gel) for Persistently Active Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2021)

A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse
por: Kaplan, Jeffrey, et al.
Publicado: (2020)

Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Askanase, Anca D., et al.
Publicado: (2020)

Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Askanase, Anca D., et al.
Publicado: (2021)

Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study
por: Furie, Richard, et al.
Publicado: (2016)

H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes
por: Kutz, Christen
Publicado: (2016)

Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study
por: Furie, Richard A, et al.
Publicado: (2017)

A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2022)

Use of Repository Corticotropin Gel (Acthar) in Progressive Nephrotic Syndrome Secondary to Transplant Glomerulopathy: A Report of Three Cases
por: Markell, Mariana, et al.
Publicado: (2019)

Repository Corticotropin Injection (Acthar(®) Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study
por: Wirta, David, et al.
Publicado: (2021)

Acthar(®) Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence
por: Kaplan, Jeffrey, et al.
Publicado: (2023)

A Narrative Review of Acthar Gel for the Treatment of Myositis
por: Chandra, Tanya, et al.
Publicado: (2023)

Results from a multicenter, randomized, double‐blind, placebo‐controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids
por: Wynn, Daniel, et al.
Publicado: (2022)

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
por: Fleischmann, Roy, et al.
Publicado: (2020)

Subcutaneous repository corticotropin gel for non-infectious panuveitis: Reappraisal of an old pharmacologic agent
por: Agarwal, Aniruddha, et al.
Publicado: (2016)

Repository corticotropin for Chronic Pulmonary Sarcoidosis
por: Baughman, Robert P., et al.
Publicado: (2017)

Acthar Gel Inhibits the Activation of CD4(+) and CD8(+) T Cells
por: Wright, Dale, et al.
Publicado: (2023)

Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis
por: Hayes, Kyle, et al.
Publicado: (2023)

Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series
por: Madan, Arvind, et al.
Publicado: (2016)

Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel
por: Zhou, Ying, et al.
Publicado: (2015)

Direct effects of HP Acthar Gel(®) on human B lymphocyte activation in vitro
por: Olsen, Nancy J., et al.
Publicado: (2015)

Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence
por: Wan, George J, et al.
Publicado: (2023)

Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies
por: Patel, Aarat, et al.
Publicado: (2016)

Treatment of fibrillary glomerulonephritis with use of repository corticotropin injections
por: Maroz, Natallia, et al.
Publicado: (2018)

Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis
por: Bindra, Jas, et al.
Publicado: (2023)

Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2022)

Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin
por: Hartung, Daniel M., et al.
Publicado: (2018)

Healthcare Costs and Resource Utilization in Patients with Infantile Spasms Treated with H.P. Acthar Gel(®)
por: Gold, Laura S., et al.
Publicado: (2016)

SARS-CoV-2 vaccines in patients with SLE
por: Tang, Wei, et al.
Publicado: (2021)

Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®)
por: Gold, Laura S., et al.
Publicado: (2016)

Safety and Efficacy of Combination ACTHar Gel and Tacrolimus in Treatment-Resistant Focal Segmental Glomerulosclerosis and Membranous Glomerulopathy
por: Tumlin, James, et al.
Publicado: (2017)

Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies
por: Fischer, Peter A, et al.
Publicado: (2018)

Treatment of Noninfectious Retinal Vasculitis Using Subcutaneous Repository Corticotropin Injection
por: Anesi, Stephen D., et al.
Publicado: (2021)

Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review
por: Mirsaeidi, Mehdi, et al.
Publicado: (2022)

The Use of COVID-19 Vaccines in Patients with SLE
por: Tang, Wei, et al.
Publicado: (2021)

Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus
por: Bindra, Jas, et al.
Publicado: (2022)

Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series
por: Brown, Alan N
Publicado: (2016)

Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis
por: Hunter, Samuel F, et al.
Publicado: (2021)

Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis
por: Busch, Howard, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m1eq9g3499b64v0r4t1u3h05en